Synapto Ventures Launches European Operational Hub in The Netherlands to Accelerate Cross-Border Life Science Capital Raising and Strategic Business Development

Press Releases

By: Press Releases

3 min read

Backed by Singapore-regulated asset manager Gold Nest Capital, Synapto Ventures B.V. establishes a dedicated continental platform bridging European life science innovators with global capital.

Synapto Ventures Pte. Ltd., the specialized corporate finance and investment advisory boutique focused exclusively on the life sciences sector of Gold Nest Capital - a Singapore-headquartered asset management company holding a Capital Markets Services (CMS) license regulated by the Monetary Authority of Singapore (MAS) - today announced the official launch of its European subsidiary, Synapto Ventures B.V., headquartered in Amsterdam. Operating within the broader Gold Nest Capital Group venture ecosystem, the new Dutch entity serves as the European operational, commercial, and due diligence hub for both Synapto Ventures' advisory mandates and Gold Nest Capital's cross-border life sciences investment platform.

The establishment of Synapto Ventures B.V. builds on more than a decade of cross-border transaction execution and venture capital activity across Europe and Asia-Pacific, including notable Dutch life sciences investments by Gold Nest Capital such as Leiden-based Mimetas. Operating out of Amsterdam places the firm at the center of Europe’s premier life sciences corridor, benefiting from proximity to the European Medicines Agency, leading university medical centers, and the Netherlands' high concentration of life science innovators.

"While European life sciences research is world-class, startups and academic spin-outs frequently encounter structural bottlenecks when scaling beyond early-stage local funding," said Emilien Dugrand, Managing Director of Synapto Ventures B.V. "By anchoring our European operations in the Netherlands, we provide founders and Technology Transfer Offices with an investor-led execution framework that bridges the translational gap and unlocks direct access to growth equity across Europe, North America, Asia-Pacific, and the Middle East."

 

Core Services of Synapto Ventures B.V.

  • Quantum Leap Capital Raising™: A non-exclusive 6-month subscription program designed for seed- to late-stage life sciences companies. The solution combines institutional-grade investor readiness and strategic roadmapping with hands-on global investor outreach.

  • BioTransfer™: A structured end-to-end venture creation framework developed for universities, research institutions, and Technology Transfer Offices. Following a commercial and technical Innovation Assessment, Synapto Ventures provides hands-on strategic and operational support - spanning IP structuring, regulatory strategy, executive recruitment, and seed financing - to transform academic innovation into investable private companies.

  • Zola™ - AI Investment Infrastructure: A proprietary multi-layer AI system engineered to transform unstructured scientific and business data into a secure, persistent, and queryable knowledge base to accelerate venture due diligence and fundraising readiness.

  • Institutional Fund Services: Synapto Ventures B.V. leads Western European deal sourcing, technical and financial due diligence, and post-investment portfolio support for Gold Nest Investment Management Pte. Ltd., the Group’s asset management company.

 

"The Netherlands has consistently demonstrated exceptional scientific density and collaborative momentum between academia, industry, and venture capital," added Edward Willems, Non-Executive Chairman of Synapto Ventures and CEO of Gold Nest Capital. "Synapto Ventures B.V. strengthens our ability to deliver on-the-ground advisory excellence while serving as a natural European landing pad for global life sciences companies in our network."

About Synapto Ventures

Synapto Ventures is a specialized corporate finance and investment advisory boutique dedicated exclusively to biotechnology, MedTech, digital health, and life science tools & services. Headquartered in Singapore with subsidiaries in the Netherlands (Synapto Ventures B.V.) and Japan (Synapto Ventures K.K.), the firm operates as the dedicated corporate finance arm of Gold Nest Capital Group, a Monetary Authority of Singapore (MAS)-licensed asset management platform. Combining PhD-level scientific rigor with institutional investment banking and venture capital expertise, Synapto Ventures breaks down the hurdles in the life science funding ecosystem by streamlining fundraising processes, benefitting both ventures and investors. The company’s mission is to be a global catalyst for life sciences, by seamlessly connecting capital with groundbreaking ideas and optimising capital flow, to empower both investors and investees in driving innovation forward.

Share this article

Advertisement

Advertisement